Reproxalap achieved the primary endpoint of improved ocular redness in patients with dry eye disease in a phase 2 clinical trial, according to a press release from Aldeyra Therapeutics.
In the randomized, double-masked, vehicle-controlled trial, 80 patients received 0.25% reproxalap ophthalmic solution, and 78 patients received vehicle ophthalmic solution.
Ocular redness scores were significantly lower in the reproxalap group than the vehicle group (P = .016). After the first dose, Schirmer’s test scores favored reproxalap, with the difference between the groups approaching significance.